Welcome to our dedicated page for Cardiff Oncology news (Ticker: CRDF), a resource for investors and traders seeking the latest updates and insights on Cardiff Oncology stock.
Cardiff Oncology, Inc. (Nasdaq: CRDF) is a clinical-stage biotechnology company developing cancer therapies based on PLK1 inhibition, with its lead asset onvansertib in multiple clinical programs. The CRDF news page on Stock Titan aggregates company announcements, clinical data updates, financial results and investor event participation so readers can follow how the onvansertib development story evolves over time.
News coverage for Cardiff Oncology frequently highlights clinical trial milestones, such as enrollment completion and data readouts from the randomized Phase 2 CRDF-004 trial in first-line RAS-mutated metastatic colorectal cancer. Press releases also describe results from investigator-initiated studies, including onvansertib in combination with paclitaxel in metastatic triple negative breast cancer and monotherapy use in chronic myelomonocytic leukemia, as well as data presented at major scientific meetings like ASCO and ASH.
Investors and observers can also find quarterly financial results and business updates, where Cardiff Oncology reports on research and development spending, cash runway and key operational highlights, alongside commentary on the progress of onvansertib across different tumor types. In addition, the company regularly announces participation in healthcare and investor conferences, including fireside chats, corporate presentations and one-on-one meetings hosted by firms such as Piper Sandler, Guggenheim, Stifel, Wells Fargo, Morgan Stanley and others.
This news feed offers a centralized view of Cardiff Oncology’s disclosures, from clinical efficacy and safety data to patent developments and leadership changes. Readers interested in oncology drug development, PLK1 inhibition, or the CRDF ticker can use this page to track Cardiff Oncology’s ongoing activities and key communications to the market.
Cardiff Oncology (Nasdaq: CRDF) reported significant progress in its Phase 1b/2 trial for KRAS-mutated colorectal cancer, showing a 37% objective response rate (ORR) with onvansertib combined with standard treatment. The median progression-free survival (mPFS) reached 9.4 months, surpassing historical controls. The company strengthened its leadership team with new appointments and ended Q3 2021 with approximately $134 million in cash, despite increased operating expenses of $7.1 million, mainly due to clinical development efforts.
Cardiff Oncology (CRDF) reported promising results from its Phase 1b/2 trial of onvansertib combined with FOLFIRI/bevacizumab for second-line treatment of KRAS-mutated metastatic colorectal cancer (mCRC). Of the 19 patients treated at the recommended dose, 42% achieved a partial response, significantly exceeding the historical 5-13% response rates. The median progression-free survival (mPFS) was 9.4 months, higher than the typical 4.5-5.7 months. The drug was well tolerated, with manageable adverse events. Further updates are expected as the trial progresses.
Cardiff Oncology (Nasdaq: CRDF), a clinical-stage oncology firm, announced its participation in two upcoming virtual investor conferences: the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021, and the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021. During these events, CEO Mark Erlander and CFO James Levine will engage in presentations and one-on-one meetings. Cardiff is focused on developing onvansertib, a novel cancer treatment targeting unmet medical needs, particularly in KRAS-mutated cancers.
Cardiff Oncology (Nasdaq: CRDF), a clinical-stage oncology company, will host a virtual KOL event on September 8, 2021, from 4:00 - 5:00 PM ET. The event will showcase new data from its Phase 1b/2 trial evaluating onvansertib in combination with FOLFIRI/bevacizumab for patients with KRAS-mutated colorectal cancer. Key speakers include Heinz-Josef Lenz and Afsaneh Barzi, with a Q&A session to follow. This event aims to inform analysts and investors about advancements in cancer treatment options.
Cardiff Oncology (Nasdaq: CRDF) reported significant advancements in its clinical development of onvansertib for difficult-to-treat cancers, including KRAS-mutated colorectal cancer and pancreatic cancer, during Q2 2021. CEO Mark Erlander highlighted crucial milestones and leadership changes, including the appointment of a new CMO and CFO. The company initiated a Phase 2 trial for metastatic pancreatic cancer and presented positive data for its colorectal cancer program, indicating enhanced patient outcomes. Financially, Cardiff holds approximately $140 million in cash, with operating expenses rising to $7 million due to clinical activities.
Cardiff Oncology, Inc. (Nasdaq: CRDF) announced the appointments of Katherine L. Ruffner, M.D. as CMO and James E. Levine as CFO on July 12, 2021. Dr. Ruffner will lead clinical programs and pipeline expansion for onvansertib, aimed at treating cancers with critical medical needs. Mr. Levine will focus on financial strategy and business development. Both bring extensive experience in their fields, aligning with the company's growth strategy around upcoming clinical milestones. The Board approved stock options for the new executives as part of their inducement to join.
Cardiff Oncology, Inc. (Nasdaq: CRDF) announced that CEO Dr. Mark Erlander will participate in a fireside chat and virtual investor meetings at the William Blair Biotech Focus Conference 2021 on July 14-15, 2021. The chat is scheduled for July 15 from 12:00 – 12:45 PM ET. Cardiff is focused on developing onvansertib, a first-in-class Polo-like Kinase 1 (PLK1) inhibitor, targeting cancers with significant medical needs, including KRAS-mutated colorectal cancer and castrate-resistant prostate cancer. More details and a webcast link are available on their website.
Cardiff Oncology (Nasdaq: CRDF) has been added to the Russell 2000, Russell 3000, and Russell Microcap indexes effective June 28, 2021. This inclusion, part of the annual reconstitution, recognizes the company's market capitalization among the largest U.S. stocks as of May 7, 2021. Membership in these indexes provides increased visibility to institutional investors, as approximately $10.6 trillion in assets benchmark against Russell's indexes. Cardiff is focused on developing onvansertib for serious cancers, including KRAS-mutated colorectal and pancreatic cancers.
Cardiff Oncology (Nasdaq: CRDF) announced the appointment of Dr. Mani Mohindru and Dr. Renee P. Tannenbaum as independent board directors, replacing outgoing members Dr. Thomas Adams and Dr. Gary Jacob. This strategic move aims to enhance corporate governance and drive future growth. Dr. Mohindru brings extensive biotech leadership experience, while Dr. Tannenbaum adds expertise in business development and strategic partnerships. Both directors aim to advance the development of onvansertib, a drug targeting cancers with high medical need.
Cardiff Oncology (Nasdaq: CRDF) announced the first patient has been dosed in a Phase 2 trial of onvansertib, combined with nanoliposomal irinotecan and 5-FU, for metastatic pancreatic ductal adenocarcinoma (PDAC). This trial targets patients who failed prior gemcitabine therapy and aims to assess safety and preliminary efficacy across 40 patients at six U.S. sites. With PDAC's poor prognosis—7.7% response rate and 3.1-month median progression-free survival—onvansertib may improve treatment outcomes for those with KRAS mutations, prevalent in 95% of PDAC cases.